Chantibody

Executive Summary

Chantibody is a private biotechnology company headquartered in Cambridge, MA, founded in 2018. The company is focused on developing a proprietary VHH (single-domain antibody) discovery platform, enabling the creation of novel multi-modality therapeutics. By leveraging the unique properties of VHH antibodies—such as small size, high stability, and ease of engineering—Chantibody aims to generate differentiated antibody-based drugs that address underserved therapeutic areas. The company's mission is to improve human health through its innovative platform and strategic collaborations, positioning itself as a key player in the next generation of antibody therapeutics.

Upcoming Catalysts (preview)

• Q3 2026First therapeutic candidate nomination from VHH platform60% success
• Q4 2026Strategic collaboration deal with major pharma50% success
• Q2 2026Series A funding round announcement70% success